MEDITECH(SH:603990) Sou Hu Cai Jing·2025-07-29 17:49Core Viewpoint - The financial performance of Madi Technology (麦迪科技) shows a significant decline in revenue while net profit has increased substantially, indicating a potential shift in operational efficiency or cost management strategies [1]. Financial Performance - As of the first quarter of 2025, the company reported total revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1]. - The net profit attributable to shareholders was 23.60 million yuan, reflecting a year-on-year increase of 138.55% [1]. - The non-recurring net profit was 2.53 million yuan, showing a year-on-year growth of 103.42% [1]. - The current ratio was 2.95, and the quick ratio was 2.82, indicating strong liquidity [1]. - The debt-to-asset ratio stood at 34.04%, suggesting a moderate level of financial leverage [1]. Market Activity - As of July 29, 2025, Madi Technology's stock closed at 16.05 yuan, with a slight increase of 0.19% [1]. - The trading volume was 138,500 hands, with a total transaction value of 222 million yuan [1]. - There was a net outflow of main funds amounting to 42.94 million yuan, which accounted for 19.32% of the transaction value [1]. - Large orders saw a net outflow of 30.92 million yuan, representing 13.91% of the transaction value [1]. Company Background - Madi Technology, officially known as Suzhou Madi Medical Technology Co., Ltd., was established in 2009 and is located in Suzhou [2]. - The company focuses primarily on research and experimental development, with a registered capital of 3,062.83 million yuan and a paid-in capital of 891.95 million yuan [2]. - The legal representative of the company is Weng Kang [1]. Investment and Intellectual Property - Madi Technology has made investments in 9 companies and participated in 3,027 bidding projects [2]. - The company holds 84 trademark registrations and 168 patents, along with 17 administrative licenses [2].